Clinical evaluation of piperacillin
Related Experiment Videos
Abstract:
28 patients with aerobic (7), anaerobic (7), and mixed (14) infections were treated with intravenous piperacillin for an average duration of 14 days. All bacterial isolates tested in this study were susceptible to piperacillin less than or equal to 128 micrograms/ml. 27 patients were treated with 20 g of piperacillin/day in four divided doses. 1 patient with renal failure received only 8 g/day. 26 patients were treated with piperacillin and two with Staphylococcus aureus infection received gentamicin in addition. The peak serum levels were 266 micrograms/ml at 1 h and the trough 16 micrograms/ml at 5 h. In all, 26 patients (93%) were 'cured', one had 'recurrence', and one 'failed'. Adverse effects were pruitus in two patients, transient elevation of LDH in one, and transient eosinophilia in another. In our preliminary study, piperacillin was found to be safe and effective in the treatment of clinical infections.
Insights
Intravenous piperacillin effectively treated aerobic, anaerobic, and mixed bacterial infections in 28 patients. This study found piperacillin safe and effective for clinical infections, with a 93% cure rate.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Microbiology
Background:
- Bacterial infections pose a significant clinical challenge.
- Effective antibiotic therapy is crucial for patient outcomes.
- Piperacillin is a broad-spectrum penicillin antibiotic.
Purpose of the Study:
- To evaluate the safety and efficacy of intravenous piperacillin in treating various bacterial infections.
- To assess treatment outcomes and adverse effects in patients receiving piperacillin.
Main Methods:
- A cohort of 28 patients with aerobic, anaerobic, and mixed infections received intravenous piperacillin.
- Dosage adjusted for renal function; some patients received additional gentamicin for Staphylococcus aureus infections.
- Bacterial susceptibility to piperacillin was confirmed; serum levels were monitored.
Main Results:
- 26 out of 28 patients (93%) achieved a 'cured' status.
- One patient experienced recurrence, and one patient had treatment failure.
- Adverse effects were mild and transient, including pruritus, elevated LDH, and eosinophilia.
Conclusions:
- Intravenous piperacillin demonstrated safety and efficacy in treating a range of bacterial infections.
- Piperacillin is a viable treatment option for aerobic, anaerobic, and mixed bacterial infections.
- Further investigation may be warranted based on these preliminary findings.